Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL)

被引：0

作者：

Bartlett, N.

Forero-Torres, A.

Rosenblatt, J.

Fanale, M.

Horning, S. J.

Thompson, S.

Sievers, E. L.

Kennedy, D. A.

机构：

[1] Washington Univ, Siteman Canc Ctr, St Louis, MO USA

[2] Univ Alabama, Birmingham, AL USA

[3] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[5] Stanford Univ, Stanford, CA 94305 USA

[6] Seattle Genet Inc, Bothell, WA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8500

引用

页数：2